Kiora Pharmaceuticals Inc (KPRX) Stock AnalysisKPRXStock AnalysisKiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kiora Pharmaceuticals Inc is currently not a strong buy due to its recent financial losses and lack of profitability. The stock price is at $2.62, with a forward P/E ratio of 2.41, indicating potential undervaluation, but the company has reported a loss of $0.58 per share in Q1 2026. The RSI is at 49.46, suggesting the stock is neither overbought nor oversold, which means it may not be the best time to buy. The main risk is the negative earnings trend, with a projected EPS of -0.34 for the last quarter, indicating ongoing financial challenges.